Clinical Trials on Influenza Vaccine

Total 3239 results

Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children

Vaccines, Pneumococcal | Vaccines, Pneumococcal Conjugate Vaccine
Centers for Disease Control and Prevention, China

Recruiting

Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 (QIV;PPV23)

Pneumococcal Vaccines | Safety | Influenza Vaccines | COVID-19 Vaccines | Immunogenicity, Vaccine

China
Pfizer

Completed

Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Vaccines, Pneumococcal Conjugate Vaccine

United States, Spain, France, Canada, Germany, Czechia, Sweden, Belgium, Poland, Netherlands
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects

Vaccines, Pneumococcal Conjugate Vaccine

South Africa
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects

Vaccines, Pneumococcal Conjugate Vaccine
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Prevenar Immunogenicity in High Risk Children

Vaccines, Pneumococcal Conjugate Vaccine
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)

Vaccines, Combined | Hexavalent Vaccine

Germany, Italy, Spain
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil

Vaccines, Pneumococcal Conjugate Vaccine

Brazil
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants

Vaccines, Pneumococcal Conjugate Vaccine

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants

Vaccines, Pneumococcal Conjugate Vaccine

Canada
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)

Vaccines, Pneumococcal Conjugate Vaccine

Philippines
Pfizer

Completed

A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older

Pneumococcal Vaccines | Pneumococcal Conjugate Vaccine

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan

Vaccines | Pneumococcal Conjugate Vaccine

Taiwan
University of Pittsburgh
Merck Sharp & Dohme LLC; Pfizer

Completed

4 Pillars Toolkit for Adolescent Vaccination

Adolescent HPV Vaccine | Adolescent Influenza Vaccine

United States
Universität des Saarlandes
Federal Institute of Sport Science

Completed

Immune Response and Risk of Side Effects After Influenza Vaccination in Athletes

Influenza Virus Vaccine Adverse Reaction | Influenza Vaccine Allergy
The Jackson Laboratory
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Recruiting

A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults (FluVax3)

Aging | Influenza Vaccine | Vaccine Response | Dendritic Cell

United States
GlaxoSmithKline

Completed

Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b | Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine

Poland, United Kingdom
Butantan Institute
University of Sao Paulo; Insituto Adolfo Lutz; Centro de Referencia e Treinamento...

Completed

Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants

Immunocompromised Patients | Safety of Pandemic Influenza A (H1N1)Vaccine | Immunogenicity of Pandemic Influenza A (H1N1)Vaccine

Brazil
University of Southern California
University of California, Los Angeles; National Institute on Aging (NIA); Los...

Completed

Precision Vaccine Promotion in Underserved Populations

Influenza | Vaccine Hesitancy

United States
University of Alberta
University of Lausanne Hospitals

Completed

Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients

Influenza Vaccine | Influenza Virus

Switzerland, Canada
Indiana University

Completed

Attitudes Toward Human Papillomavirus and Influenza Vaccination Among Mothers of Early Adolescents

Influenza Vaccines | Human Papillomavirus Vaccines | Attitude to Health
King's College London

Completed

Factors Associated With Parental Observation of Side Effects Following the Child Flu Vaccine

Influenza Vaccine, Influenza

United Kingdom
St. Petersburg Research Institute of Vaccines and...

Completed

Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b

Vaccines | Haemophilus Influenzae Infection

Russian Federation
Vanderbilt University Medical Center
Human Vaccines Project

Completed

Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults (KIRV)

Vaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines

Prophylaxis of Avian Influenza Vaccine

United Kingdom
University of Michigan

Completed

Memory for Flu Facts and Myths and Effects on Vaccine Intentions

Influenza Vaccines

United States, Canada
FluGen Inc
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old

Influenza Vaccine

United States
FluGen Inc
United States Department of Defense

Completed

Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults

Influenza Vaccine

United States
MedImmune LLC

Completed

A Phase 2 Study to Evaluate Immune Responses of FluMist®

Influenza Vaccine

United States
University of British Columbia
PHAC/CIHR Influenza Research Network

Completed

Comparison of 4 Influenza Vaccines in Seniors (PCIRNRT09)

Influenza Vaccine

Canada
Medigen Vaccine Biologics Corp.

Completed

A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects

H7N9 Influenza Vaccine

Taiwan
AB Biotics, SA

Completed

Effect of a Multi-strain Probiotic Formulation on Immune Response to Influenza Vaccination (FLUVAC21)

Influenza Vaccine

Spain
University of Alberta

Completed

Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients

Influenza Vaccine

Canada
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China

Completed

Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine

Prevention | Pandemic Influenza | Pandemic Influenza Vaccine

China
MedImmune LLC
AstraZeneca

Suspended

A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age (ICICLE)

Influenza Vaccine Effectiveness

United States, United Kingdom
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects

Prepandemic Influenza Vaccine

Hungary
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009

Seasonal Influenza, Vaccine

Germany
Novartis Vaccines

Completed

Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions

Seasonal Influenza | Vaccine

Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008

Seasonal Influenza Vaccine

Germany
Seattle Children's Hospital
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age (GRC28)

Inactivated Influenza Vaccine

United States
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008

Seasonal Influenza | Vaccine

Germany
University of Warwick

Completed

Influenza 2020/2021

Influenza Vaccine

United Kingdom
PATH
Institute of Experimental Medicine, Russia; Research Institute of Influenza...

Completed

Immunogenicity of H5N1 Vaccine Following H5N2

Influenza Vaccine

Russian Federation
Green Cross Corporation

Unknown

A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age

Influenza Vaccine

Korea, Republic of
Association Clinique Thérapeutique Infantile du...
Pfizer

Recruiting

National Bacterial Meningitis Study

Meningitis | Children, Only | Neonatal Infection | Meningococcal Vaccines | Pneumococcal Conjugate Vaccine | Antibiotic Treatment | H. Influenzae Vaccine | Case Fatality Rate

France
Beijing Chaoyang District Centre for Disease Control...

Completed

Safety Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged 3 Years and Older

Quadrivalent Influenza Virus Vaccine

China
Vanderbilt University
Centers for Disease Control and Prevention

Completed

Cell Mediated Immunity in Older Adults (CMI)

Immunity to Influenza Vaccine

United States
Johns Hopkins Bloomberg School of Public Health

Completed

Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study

Influenza Virus Vaccine

United States
Vaxart

Completed

Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults

Seasonal Influenza Preventative Vaccine Pharmacodynamics

United States
University of Lausanne Hospitals

Completed

Imiquimod and Influenza Vaccine for Immunocompromised Patients (IMIFLU)

Influenza Vaccine

Switzerland

Clinical Trials on Influenza Vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations